E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 10/23/2009 in the Prospect News Special Situations Daily.

Merck, Schering-Plough merger expected to close in fourth quarter

By Lisa Kerner

Charlotte, N.C., Oct. 23 - The European Commission granted its approval for the proposed merger of Merck & Co., Inc. and Schering-Plough Corp., the companies announced on Friday.

Merck and Schering-Plough said they expect to close the transaction in the fourth quarter of 2009.

Shareholders of both companies approved the merger in August.

In March 2009, the pharmaceutical companies announced that Merck will acquire Schering-Plough in a stock-and-cash transaction valued at $41.1 billion, or approximately $23.61 per share.

Schering-Plough shareholders will receive 0.5767 shares of new Merck common stock and $10.50 in cash for each share of Schering-Plough. Each Merck share will automatically become a share of the combined company.

Merck is based in Whitehouse Station, N.J., and Schering-Plough is based in Kenilworth, N.J.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.